Which has higher valuation & earnings, IDN or CXDO?

Crexendo has higher revenue and earnings than Intellicheck. Intellicheck is trading at a lower price-to-earnings ratio than Crexendo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intellicheck $22.67M 2.64 $1.27M $0.15 19.67 Crexendo $68.17M 3.12 $5.07M $0.14 45.64

Is IDN or CXDO more profitable?

Intellicheck has a net margin of 13.03% compared to Crexendo's net margin of 5.31%. Intellicheck's return on equity of 15.02% beat Crexendo's return on equity. Company Net Margins Return on Equity Return on Assets Intellicheck 13.03% 15.02% 12.27% Crexendo 5.31% 14.34% 11.44%

Does the media prefer IDN or CXDO?

In the previous week, Intellicheck had 4 more articles in the media than Crexendo. MarketBeat recorded 8 mentions for Intellicheck and 4 mentions for Crexendo. Crexendo's average media sentiment score of 1.18 beat Intellicheck's score of 0.66 indicating that Crexendo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellicheck 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crexendo 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, EGAN or IDN?

eGain has higher revenue and earnings than Intellicheck. eGain is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eGain $92.22M 2.17 $32.25M $1.38 5.29 Intellicheck $22.67M 2.64 $1.27M $0.15 19.67

Is EGAN or IDN more profitable?

eGain has a net margin of 41.68% compared to Intellicheck's net margin of 13.03%. Intellicheck's return on equity of 15.02% beat eGain's return on equity. Company Net Margins Return on Equity Return on Assets eGain 41.68% 12.56% 7.48% Intellicheck 13.03% 15.02% 12.27%

Do analysts prefer ZSQR or IDN?

Intellicheck has a consensus price target of $6.50, indicating a potential upside of 120.34%. Given Intellicheck's stronger consensus rating and higher possible upside, analysts clearly believe Intellicheck is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intellicheck 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate PERF or IDN?

Intellicheck has a consensus target price of $6.50, indicating a potential upside of 120.34%. Given Intellicheck's stronger consensus rating and higher possible upside, analysts clearly believe Intellicheck is more favorable than Perfect. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perfect 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Intellicheck 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, PERF or IDN?

Perfect has higher revenue and earnings than Intellicheck. Intellicheck is trading at a lower price-to-earnings ratio than Perfect, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perfect $71.07M 2.67 $4.64M $0.06 31.08 Intellicheck $22.67M 2.64 $1.27M $0.15 19.67

Is PERF or IDN more profitable?

Intellicheck has a net margin of 13.03% compared to Perfect's net margin of 8.13%. Intellicheck's return on equity of 15.02% beat Perfect's return on equity. Company Net Margins Return on Equity Return on Assets Perfect 8.13% 3.73% 2.98% Intellicheck 13.03% 15.02% 12.27%

Does the media favor PERF or IDN?

In the previous week, Intellicheck had 6 more articles in the media than Perfect. MarketBeat recorded 8 mentions for Intellicheck and 2 mentions for Perfect. Perfect's average media sentiment score of 1.17 beat Intellicheck's score of 0.66 indicating that Perfect is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perfect 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellicheck 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IDN or EXFY more profitable?

Intellicheck has a net margin of 13.03% compared to Expensify's net margin of -11.31%. Intellicheck's return on equity of 15.02% beat Expensify's return on equity. Company Net Margins Return on Equity Return on Assets Intellicheck 13.03% 15.02% 12.27% Expensify -11.31% -11.54% -8.34%

Intellicheck (IDN) Competitors

$2.95 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

IDN vs. CXDO, EGAN, ZSQR, PERF, and EXFY

Should you buy Intellicheck stock or one of its competitors? Intellicheck's main competitors and comparable companies include Crexendo (CXDO), eGain (EGAN), Coeptis Therapeutics (ZSQR), Perfect (PERF), and Expensify (EXFY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Intellicheck compare to Crexendo?

Intellicheck (NASDAQ:IDN) and Crexendo (NASDAQ:CXDO) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Crexendo has higher revenue and earnings than Intellicheck. Intellicheck is trading at a lower price-to-earnings ratio than Crexendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellicheck	$22.67M	2.64	$1.27M	$0.15	19.67
Crexendo	$68.17M	3.12	$5.07M	$0.14	45.64

Intellicheck has a net margin of 13.03% compared to Crexendo's net margin of 5.31%. Intellicheck's return on equity of 15.02% beat Crexendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellicheck	13.03%	15.02%	12.27%
Crexendo	5.31%	14.34%	11.44%

42.8% of Intellicheck shares are held by institutional investors. Comparatively, 9.5% of Crexendo shares are held by institutional investors. 7.8% of Intellicheck shares are held by company insiders. Comparatively, 47.2% of Crexendo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Intellicheck had 4 more articles in the media than Crexendo. MarketBeat recorded 8 mentions for Intellicheck and 4 mentions for Crexendo. Crexendo's average media sentiment score of 1.18 beat Intellicheck's score of 0.66 indicating that Crexendo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellicheck	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Crexendo	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellicheck has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Crexendo has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Intellicheck currently has a consensus price target of $6.50, suggesting a potential upside of 120.34%. Crexendo has a consensus price target of $10.50, suggesting a potential upside of 64.32%. Given Intellicheck's higher probable upside, equities analysts clearly believe Intellicheck is more favorable than Crexendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Crexendo	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Crexendo beats Intellicheck on 8 of the 15 factors compared between the two stocks.

How does Intellicheck compare to eGain?

eGain (NASDAQ:EGAN) and Intellicheck (NASDAQ:IDN) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

eGain has higher revenue and earnings than Intellicheck. eGain is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eGain	$92.22M	2.17	$32.25M	$1.38	5.29
Intellicheck	$22.67M	2.64	$1.27M	$0.15	19.67

53.9% of eGain shares are owned by institutional investors. Comparatively, 42.8% of Intellicheck shares are owned by institutional investors. 38.7% of eGain shares are owned by insiders. Comparatively, 7.8% of Intellicheck shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

eGain has a net margin of 41.68% compared to Intellicheck's net margin of 13.03%. Intellicheck's return on equity of 15.02% beat eGain's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eGain	41.68%	12.56%	7.48%
Intellicheck	13.03%	15.02%	12.27%

eGain presently has a consensus target price of $15.25, indicating a potential upside of 108.90%. Intellicheck has a consensus target price of $6.50, indicating a potential upside of 120.34%. Given Intellicheck's stronger consensus rating and higher probable upside, analysts plainly believe Intellicheck is more favorable than eGain.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eGain	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

eGain has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Intellicheck has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, Intellicheck had 8 more articles in the media than eGain. MarketBeat recorded 8 mentions for Intellicheck and 0 mentions for eGain. Intellicheck's average media sentiment score of 0.66 beat eGain's score of 0.00 indicating that Intellicheck is being referred to more favorably in the news media.

Company	Overall Sentiment
eGain	Neutral
Intellicheck	Positive

Summary

Intellicheck beats eGain on 9 of the 15 factors compared between the two stocks.

How does Intellicheck compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Intellicheck (NASDAQ:IDN) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Intellicheck has a net margin of 13.03% compared to Coeptis Therapeutics' net margin of -773.72%. Intellicheck's return on equity of 15.02% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Intellicheck	13.03%	15.02%	12.27%

In the previous week, Intellicheck had 7 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 8 mentions for Intellicheck and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.00 beat Intellicheck's score of 0.66 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coeptis Therapeutics	Positive
Intellicheck	Positive

Intellicheck has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A
Intellicheck	$22.67M	2.64	$1.27M	$0.15	19.67

Intellicheck has a consensus price target of $6.50, indicating a potential upside of 120.34%. Given Intellicheck's stronger consensus rating and higher possible upside, analysts clearly believe Intellicheck is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Coeptis Therapeutics has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market. Comparatively, Intellicheck has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Intellicheck shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 7.8% of Intellicheck shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Intellicheck beats Coeptis Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Intellicheck compare to Perfect?

Perfect (NYSE:PERF) and Intellicheck (NASDAQ:IDN) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Intellicheck has a net margin of 13.03% compared to Perfect's net margin of 8.13%. Intellicheck's return on equity of 15.02% beat Perfect's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perfect	8.13%	3.73%	2.98%
Intellicheck	13.03%	15.02%	12.27%

Intellicheck has a consensus target price of $6.50, indicating a potential upside of 120.34%. Given Intellicheck's stronger consensus rating and higher possible upside, analysts clearly believe Intellicheck is more favorable than Perfect.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perfect	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Intellicheck had 6 more articles in the media than Perfect. MarketBeat recorded 8 mentions for Intellicheck and 2 mentions for Perfect. Perfect's average media sentiment score of 1.17 beat Intellicheck's score of 0.66 indicating that Perfect is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perfect	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellicheck	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Perfect has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Intellicheck has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Perfect has higher revenue and earnings than Intellicheck. Intellicheck is trading at a lower price-to-earnings ratio than Perfect, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perfect	$71.07M	2.67	$4.64M	$0.06	31.08
Intellicheck	$22.67M	2.64	$1.27M	$0.15	19.67

42.8% of Intellicheck shares are owned by institutional investors. 44.7% of Perfect shares are owned by company insiders. Comparatively, 7.8% of Intellicheck shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Intellicheck beats Perfect on 10 of the 16 factors compared between the two stocks.

How does Intellicheck compare to Expensify?

Intellicheck (NASDAQ:IDN) and Expensify (NASDAQ:EXFY) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Intellicheck has higher earnings, but lower revenue than Expensify. Expensify is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellicheck	$22.67M	2.64	$1.27M	$0.15	19.67
Expensify	$142.10M	1.47	-$21.39M	-$0.17	N/A

Intellicheck presently has a consensus price target of $6.50, suggesting a potential upside of 120.34%. Expensify has a consensus price target of $3.00, suggesting a potential upside of 13.64%. Given Intellicheck's stronger consensus rating and higher possible upside, analysts plainly believe Intellicheck is more favorable than Expensify.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Expensify	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Intellicheck has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Expensify has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

42.8% of Intellicheck shares are owned by institutional investors. Comparatively, 68.4% of Expensify shares are owned by institutional investors. 7.8% of Intellicheck shares are owned by company insiders. Comparatively, 11.7% of Expensify shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Intellicheck has a net margin of 13.03% compared to Expensify's net margin of -11.31%. Intellicheck's return on equity of 15.02% beat Expensify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellicheck	13.03%	15.02%	12.27%
Expensify	-11.31%	-11.54%	-8.34%

In the previous week, Intellicheck had 8 more articles in the media than Expensify. MarketBeat recorded 8 mentions for Intellicheck and 0 mentions for Expensify. Intellicheck's average media sentiment score of 0.66 beat Expensify's score of 0.55 indicating that Intellicheck is being referred to more favorably in the media.

Company	Overall Sentiment
Intellicheck	Positive
Expensify	Positive

Summary

Intellicheck beats Expensify on 12 of the 16 factors compared between the two stocks.

Get Intellicheck News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDN vs. The Competition

Export

Metric	Intellicheck	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$59.79M	$15.67B	$29.53B	$12.85B
Dividend Yield	N/A	3.42%	2.75%	11.08%
P/E Ratio	19.67	127.26	73.35	24.24
Price / Sales	2.64	1,303.59	598.84	99.78
Price / Cash	30.16	48.13	50.35	53.99
Price / Book	2.66	7.50	9.44	6.20
Net Income	$1.27M	$434.60M	$679.74M	$348.59M
7 Day Performance	4.98%	1.62%	-1.29%	0.08%
1 Month Performance	-19.62%	7.50%	4.03%	3.88%
1 Year Performance	-44.55%	5.00%	189.70%	16.98%

Intellicheck Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDN Intellicheck	3.1272 of 5 stars	$2.95 flat	$6.50 +120.3%	-44.5%	$59.79M	$22.67M	19.67	50	Analyst Revision
CXDO Crexendo	4.4358 of 5 stars	$6.65 +1.7%	$10.50 +57.9%	+4.8%	$221.14M	$68.17M	47.50	120	Positive News
EGAN eGain	1.73 of 5 stars	$7.50 -0.1%	$15.25 +103.3%	+14.1%	$205.88M	$88.43M	5.43	690
ZSQR Coeptis Therapeutics	0.5559 of 5 stars	$3.94 -5.3%	N/A	-72.9%	$202.64M	$1.36M	N/A	2	Positive News
PERF Perfect	1.6445 of 5 stars	$1.87 -0.5%	N/A	-3.1%	$190.46M	$69.15M	31.17	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellicheck (IDN) Competitors

IDN vs. CXDO, EGAN, ZSQR, PERF, and EXFY

How does Intellicheck compare to Crexendo?

Summary

How does Intellicheck compare to eGain?

Summary

How does Intellicheck compare to Coeptis Therapeutics?

Summary

How does Intellicheck compare to Perfect?

Summary

How does Intellicheck compare to Expensify?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDN vs. The Competition

Intellicheck Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellicheck (IDN) Competitors

IDN vs. CXDO, EGAN, ZSQR, PERF, and EXFY

How does Intellicheck compare to Crexendo?

Which has higher valuation & earnings, IDN or CXDO?

Is IDN or CXDO more profitable?

Do institutionals & insiders have more ownership in IDN or CXDO?

Does the media prefer IDN or CXDO?

Which has more volatility and risk, IDN or CXDO?

Do analysts recommend IDN or CXDO?

Summary

How does Intellicheck compare to eGain?

Which has better valuation and earnings, EGAN or IDN?

Do institutionals and insiders believe in EGAN or IDN?

Is EGAN or IDN more profitable?

Do analysts prefer EGAN or IDN?

Which has more volatility and risk, EGAN or IDN?

Does the media favor EGAN or IDN?

Summary

How does Intellicheck compare to Coeptis Therapeutics?

Is ZSQR or IDN more profitable?

Does the media favor ZSQR or IDN?

Which has higher valuation & earnings, ZSQR or IDN?

Do analysts prefer ZSQR or IDN?

Which has more risk & volatility, ZSQR or IDN?

Do institutionals & insiders believe in ZSQR or IDN?

Summary

How does Intellicheck compare to Perfect?

Is PERF or IDN more profitable?

Do analysts rate PERF or IDN?

Does the media favor PERF or IDN?

Which has more risk and volatility, PERF or IDN?

Which has better earnings & valuation, PERF or IDN?

Do institutionals and insiders hold more shares of PERF or IDN?

Summary

How does Intellicheck compare to Expensify?

Which has stronger valuation & earnings, IDN or EXFY?

Do analysts rate IDN or EXFY?

Which has more risk & volatility, IDN or EXFY?

Do institutionals & insiders hold more shares of IDN or EXFY?

Is IDN or EXFY more profitable?

Does the media refer more to IDN or EXFY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDN vs. The Competition

Intellicheck Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools